Neurology Sales

Job Description

Join the Team Bringing PET-Quality Brain Imaging into Every Alzheimer’s Practice – Commission-Only, High-Ticket Closer Role

Vistim Labs has launched a breakthrough neurodiagnostic platform that turns a routine 20-minute EEG into structural brain images clinically indistinguishable from amyloid-PET scans, validated side-by-side against real PET in clinical studies.

We are looking for one or two elite neurology / medical device salespeople who still love the hunt and want to be the first to bring this to private Alzheimer’s and memory-disorder practices across the U.S.

Why this is different (and why the best reps are already reaching out) :

• Practices desperately need objective proof that expensive Alzheimer’s therapies (Leqembi, Kisunla, donanemab, etc.) are actually clearing amyloid and slowing atrophy. Until now the only gold-standard proof was a $6,000–$8,000 PET scan involving radioactivity, long wait times, and prior authorizations most patients never get.
• Our SaaS delivers monthly, in-office, radiation-free, PET-equivalent amyloid and tau imaging for a fraction of the cost, partially reimbursed, and performed with equipment they already own.
• One scan = visible, patient-specific before / after images that turn “I hope this is working” into “Look, your amyloid plaque dropped 38% in six months.” Retention skyrockets, outcomes improve, and practices finally have an evidence-based reason to keep patients in-house instead of referring out.

Your role

100% hunting, zero inside leads provided at this stage. You source, qualify, demo, and close.

Average contract value : $35–70k first-year per clinic (multi-chair practices routinely go higher).

Commission : ~$4,000–$8,000 paid on signing (wire same week). Top performers who open 4–6 new accounts per month could clear $250k–$450k+ in year one, entirely commission-only.

Who succeeds here

You’ve sold into neurology, functional medicine, or Alzheimer’s / memory centers before (devices, pharma, diagnostics, or infusion services).

You still have a warm network of private-practice neurologists, geriatric psychiatrists, or high-volume memory clinics.

You can credibly speak the language of amyloid clearance, tau staging, cents-per-QALY, and CMS reimbursement.

You are comfortable being the first rep in the field with a brand-new category; limited marketing assets right now (we have clinical data, published validation, live demos, and a handful of ecstatic early adopters, but no glossy brochures or big booth at AAN yet).

This is early-stage, high-leverage, and genuinely changes lives. Every practice you open keeps dozens of patients from unnecessary radiation, months of uncertainty, or being told “we’ll just wait another year and see.” Patients literally cry when they see their own brain improving for the first time.

If you have the network, the closer mentality, and want to own a territory in one of the most important medical breakthroughs in dementia care in the last decade, reply with your brief track record and why this specific problem excites you.

We move fast and are highly selective; only proven hunters who can start having meaningful conversations in the next 30 days.

Looking forward to building this with you.

Vistim Labs Leadership Team